Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Prognostic Significance Of Ki67 Expression In Malignant Peritoneal Mesothelioma

K. Pillai, M. Pourgholami, T. Chua, D. Morris
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Objectives:Although Ki67 measurement by immunohistochemistry has been widely used as a prognostic index in cancers, it has not been reported in malignant peritoneal mesothelioma (MPM). Hence, this study examines the prognostic significance of Ki67 in MPM. Methods:Specimens from 42 MPM patients were screened for Ki67 expression using immunohistochemistry. Ki67 expression was classified into 2 groups on the basis of expression (<25%=low; ≥25%=high) using standard methods. Using Kaplan-Meier survival analysis, the significance of Ki67 was assessed in different clinicopathologic categories. Results:High expression of Ki67 (≥25% by immunohistochemical evaluation) was correlated with poor survival in the overall group (P=0.001); male sex (P=0.001); female sex (P=0.001); epithelioid tumors (P=0.001): male epithelioid (P=0.001), female epithelioid (P=0.003); peritoneal cancer index (PCI): PCI<20 (P=0.001), PCI≥20 (P=0.002); and age at diagnosis (AAD): AAD<60 years (P=0.001), AAD≥60 years (P=0.004). Independent of Ki67, male sex (P=0.007), sarcomatoid histology (P=0.001), PCI≥20 (P=0.013), and AAD≥60 years (P=0.004) correlated with poor survival. Multivariate analysis showed that only AAD≥60 years (P=0.049) and high Ki67 expression for all tumors (P=0.031), male sex (P=0.038), female sex (P=0.021), epithelioid tumors (P=0.044), and AAD<60 years (P=0.029) were statistically significant. Conclusions:Ki67 expression affects prognosis in MPM patients and helps to predict survival within the various clinicopathologic categories.
This paper references
10.1002/IJC.2910310104
Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation
J. Gerdes (1983)
10.1007/s10549-008-0081-7
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
R. Jones (2008)
10.1002/ijc.24174
Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small‐volume or low‐grade prostate cancer
T. Zellweger (2009)
10.1007/s00432-013-1408-2
Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma
K. Pillai (2013)
10.1016/S0140-6736(02)09088-8
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
M. Baum (2002)
10.1124/mol.107.039974
17β-Estradiol Promotes Breast Cancer Cell Proliferation-Inducing Stromal Cell-Derived Factor-1-Mediated Epidermal Growth Factor Receptor Transactivation: Reversal by Gefitinib Pretreatment
A. Pattarozzi (2008)
10.1245/ASO.2006.03.045
Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion
M. Deraco (2006)
Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies.
J. Gerdes (1990)
10.1080/13685530701600885
Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research
L. Gooren (2007)
10.1200/JCO.2009.23.9640
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
T. Yan (2009)
10.1043/1543-2165(2006)130[1654:PSOHPI]2.0.CO;2
Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma.
C. Cerruto (2006)
10.1158/0008-5472.CAN-10-1190
Ki-67 as a molecular target for therapy in an in vitro three-dimensional model for ovarian cancer.
R. Rahmanzadeh (2010)
10.1007/s00795-009-0460-0
Malignant mesothelioma of the peritoneum: case reports and immunohistochemical findings including Ki-67 expression
H. Hirano (2009)
10.1186/1477-7819-8-88
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma
J. Foster (2010)
10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
The Ki‐67 protein: From the known and the unknown
T. Scholzen (2000)
The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression.
M. Starborg (1996)
10.1016/j.critrevonc.2008.03.005
The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region.
B. V. van Leeuwen (2008)
10.1016/S1470-2045(09)70028-2
Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England.
B. Rachet (2009)
10.1002/cncr.25640
A novel tumor‐node‐metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi‐institutional database *
T. Yan (2011)
10.1158/1535-7163.MCT-08-0684
Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
J. D. Orth (2008)
Peritoneal mesothelioma: current understanding and management
T. Chua (2009)
Immunohistochemical staining of mucin 1 in prostate tissues.
N. Rabiau (2009)
The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.
Guro Aune (2011)
Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.
T. Chua (2009)
10.1200/JCO.2010.30.2075
Impact of age at diagnosis on prostate cancer treatment and survival.
Seth K. Bechis (2011)
Ki-67 detects a nuclear matrix-associated proliferation-related antigen. I. Intracellular localization during interphase.
R. Verheijen (1989)
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.
J. Gerdes (1984)
10.1023/A:1015764507609
Effect of young age on prostate cancer survival: a population-based assessment (United States)
R. Merrill (2004)
10.1158/0008-5472.CAN-10-4336
Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
Jue Shi (2011)
10.1158/0008-5472.CAN-08-4523
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
G. Pinton (2009)
10.1183/09031936.00000811
Predicting survival in malignant mesothelioma
A. Musk (2011)
10.1245/s10434-006-9169-7
Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma†
T. Yan (2006)
10.1021/CR0306743
Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy.
M. Famulok (2007)
10.1186/1471-2407-6-203
Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer
J. Yang (2006)
10.1046/j.1365-2559.2003.01613.x
Colorectal carcinomas with high MIB‐1 labelling indices but low pKi67 mRNA levels correlate with better prognostic outcome
M. Duchrow (2003)
10.1186/1471-2407-11-486
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
P. Fasching (2011)
10.1091/mbc.E10-04-0335
The proliferation rate paradox in antimitotic chemotherapy
T. Mitchison (2012)
Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up.
D. Lazăr (2010)
10.1093/JNCI/DJK020
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
M. Dowsett (2007)
10.1111/j.1365-2559.2011.04108.x
High Wilms’ tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelioma
A. Scattone (2012)
10.1093/annonc/mdr477
Importance of gender in diffuse malignant peritoneal mesothelioma.
C. Cao (2012)
10.1007/s12253-009-9170-0
Differential Expression of Ki-67 and Sex Steroid Hormone Receptors Between Genders in Peritoneal Mesothelioma
Terence C. Chua (2009)
10.1200/JCO.2010.31.2835
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
J. Cuzick (2011)
10.1200/JCO.2008.18.2808
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
F. Penault-Llorca (2009)
10.1177/000313481007600418
Risk Factors and Clinicopathological Study of Prognostic Factors in the Peritoneal Mesothelioma
E. C. Tudor (2010)



This paper is referenced by
10.1038/s41379-020-00688-4
Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases
David B. Chapel (2020)
10.7150/jca.20935
Ki67 Proliferation Index as a Histopathological Predictive and Prognostic Parameter of Oral Mucosal Melanoma in Patients without Distant Metastases
X. Ma (2017)
10.1007/978-3-319-99510-6_4
Standardizing of Mesothelioma and Pseudomyxoma Care
Ranyell Spencer Sobreira Batista (2019)
10.1590/0100-69912017005016
A proposal of Brazilian Society of Surgical Oncology (BSSO/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma
T. Batista (2017)
A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil : pseudomixoma peritonei , appendiceal tumors and malignant peritoneal mesothelioma
P. Batista (2017)
10.1016/j.lungcan.2018.11.032
Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
D. Chapel (2019)
10.30944/20117582.445
Manejo del mesotelioma peritoneal maligno con citorreducción quirúrgica más quimioterapia hipertérmica intraperitoneal en el Instituto Nacional de Cancerología, Colombia: reporte de un caso y revisión bibliográfica
Juliana Restrepo lópez (2019)
10.1038/s41591-019-0583-3
Deep learning-based classification of mesothelioma improves prediction of patient outcome
Pierre Courtiol (2019)
10.3390/diagnostics10060386
Prognostic Value of Ki67 Percentage, WT-1 Expression and p16/CDKN2A Deletion in Diffuse Malignant Peritoneal Mesothelioma: A Single-Centre Cohort Study
Federica Pezzuto (2020)
10.1016/j.soc.2018.02.012
Patient Selection for Cytoreductive Surgery.
T. Grotz (2018)
10.1371/journal.pone.0186137
Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models
M. Alfaleh (2017)
10.1016/j.humpath.2020.08.005
The potential utility of GATA3 for diagnosis of malignant pleural mesotheliomas.
Sarita Prabhakaran (2020)
10.1080/02656736.2018.1434902
Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival
S. N. Gilani (2018)
10.5772/intechopen.91769
Predictive and Prognosis Factors of Clinical Utility in Mesothelioma
Rodríguez-Cid Jeronimo Rafael (2020)
Semantic Scholar Logo Some data provided by SemanticScholar